Want to join the conversation?
$ALXN 2Q15 Call: Including Strensiq & Kanuma, company now has 8 product candidates in the clinic for 11 indications and expects at least four additional programs to enter the clinic in 2016. In late-stage pipeline, ALXN has exceeded its enrollment target in the eculizumab registration trial in refractory MG and expects preliminary data in mid-2016.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?
After so much controversy and family issues in $VIAB over the recent months, Paramount brings in some good news. News is that they signed a $1 billion deal with Shanghai Film Group and Huahua Media. The material impact to Viacom however is still uncertain.